Drugs / omega interferon
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00519792 | Aug 2007 → Mar 2010 | chronic hepatitis C virus infection | Intarcia Therapeutics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00097045 | Nov 2004 → Dec 2006 | hepatitis C virus infection | Intarcia Therapeutics | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | omega interferon | “Omega DUROS® is an implantable drug delivery system designed to deliver omega interferon subcutaneously at a constant rate for 90 days.” NCT00519792 ↗ |
| Route | Subcutaneous | “Omega interferon is administered subcutaneously daily for up to 48 weeks.” NCT00097045 ↗ |